Other · developed by ASTRAZENECA
AZD4954 is a drug studied as a single oral dose (tablet or solution) and as a radiolabelled ([14C]) intravenous infusion in healthy participants.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07812077 | Phase 1 | Healthy Participants | Recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Participants
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →